Dong-Hang Xu Selected Research

Doxorubicin (Adriamycin)

1/2021	Mitochondrial targeted doxorubicin derivatives delivered by ROS-responsive nanocarriers to breast tumor for overcoming of multidrug resistance.
10/2012	Overcoming drug resistance of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Dong-Hang Xu Research Topics

Disease

6	Neoplasms (Cancer) 01/2021 - 11/2008
3	Breast Neoplasms (Breast Cancer) 01/2021 - 10/2012
1	Hemolysis 04/2009
1	Carcinoma (Carcinomatosis) 11/2008
1	Glioma (Gliomas) 07/2008

Drug/Important Bio-Agent (IBA)

2	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021 - 10/2012
2	Proteins (Proteins, Gene)FDA Link 04/2009 - 07/2008
1	Hyaluronic Acid (Hyaluronan)IBA 01/2021
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2021
1	LigandsIBA 01/2021
1	AcetalsIBA 09/2019
1	MicellesIBA 09/2019
1	SolutionsIBA 10/2012
1	major vault proteinIBA 10/2012
1	Phosphates (Orthophosphate)IBA 04/2009
1	10-methoxy-9-nitrocamptothecinIBA 04/2009
1	BuffersIBA 04/2009
1	CamptothecinIBA 04/2009
1	lissamine rhodamine B (sulforhodamine B)IBA 04/2009
1	Coloring Agents (Dyes)IBA 04/2009
1	SaltsIBA 04/2009
1	Chemokine CCL27IBA 02/2009
1	Chemotactic FactorsIBA 02/2009
1	6-sulfo sialyl Lewis XIBA 02/2009
1	Interleukin-12 (IL 12)IBA 11/2008
1	ChemokinesIBA 11/2008
1	CytokinesIBA 11/2008
1	Liposomes (Liposome)IBA 07/2008
1	elemeneIBA 07/2008
1	Caspase 3 (Caspase-3)IBA 07/2008

Therapy/Procedure

3	Drug Therapy (Chemotherapy) 01/2021 - 04/2009
1	Immunotherapy 11/2008